Evidence map›Paper›PMID 24077291›Full record

ArticleOncogene2014

Inhibition of monocarboxylate transporter-4 depletes stem-like glioblastoma cells and inhibits HIF transcriptional response in a lactate-independent manner.

K S Lim, K J Lim, A C Price, B A Orr, C G Eberhart, E E Bar

Open access · bronzeAbstract read
In one paragraph

Article in Oncogene, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Lactate and lactylation in cancer.Signal transduction and targeted therapy · 2025
    Review
  7. Glioblastoma stem cell metabolism and immunity.Cancer metastasis reviews · 2024
    Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Regulation of Transactivation at C-TAD Domain of HIF-1Oxidative medicine and cellular longevity · 2022
    Review
  17. The role of SLC transporters for brain health and disease.Cellular and molecular life sciences : CMLS · 2021
    Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

K S LimDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
K J LimDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
A C PriceDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
B A OrrDepartment of Pathology, St Jude Children's Research Hospital, Memphis, TN, USA.
C G Eberhart1] Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA [2] Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA [3] Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
E E Bar1] Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA [2] Department of Neurosurgery, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Johns Hopkins University · USJohns Hopkins Medicine · USSt. Jude Children's Research Hospital · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
Notch signaling in brain tumorsR01NS055089 · NINDS · JOHNS HOPKINS UNIVERSITY · PI EBERHART, CHARLES G · 2007 to 2016
$3.2M
NCI NIH HHS P30 CA006973NINDS NIH HHS R01 NS055089NINDS NIH HHS R01 NS55089
6 · The paper itself

Abstract

Hypoxic regions are frequent in glioblastoma (GBM), the most common type of malignant adult brain tumor, and increased levels of tumor hypoxia have been associated with worse clinical outcomes. To unmask genes important in hypoxia, we treated GBM neurospheres in hypoxia and identified monocarboxylate transporter-4 (MCT4) as one of the most upregulated genes. To investigate the clinical importance of MCT4 in GBM, we examined clinical outcomes and found that MCT4 overexpression is associated with shorter patient survival. Consistent with this, MCT4 upregulation correlated with the aggressive mesenchymal subset of GBM, and MCT4 downregulation correlated with the less aggressive G-CIMP (Glioma CpG Methylator Phenotype) subset of GBM. Immunohistochemical analysis of tissue microarrays confirmed that MCT4 protein levels were increased in high-grade as compared with lower-grade astrocytomas, further suggesting that MCT4 is a clinically relevant target. To test the requirement for MCT4 in vitro, we transduced neurospheres with lentiviruses encoding short-hairpin RNAs (shRNAs) against MCT4, resulting in growth inhibition of 50-80% under hypoxia in two lines. MCT4 knockdown was associated with a decreased percentage of cells expressing the stem-cell marker CD133 and increased apoptotic fraction. We also found that flow-sorted CD133-positive cells had almost sixfold higher MCT4 levels than CD133-negative cells, suggesting that the stem-like population might have a greater requirement for MCT4. Most importantly, MCT4 silencing also slowed GBM intracranial xenograft growth in vivo. Interestingly, whereas MCT4 is a well-characterized lactate exporter, we found that both intracellular and extracellular lactate levels did not change following MCT4 silencing, suggesting a novel lactate export-independent mechanism for growth inhibition in GBMs. To identify this potential mechanism, we performed microarray analysis on control and shMCT4-expressing neurospheres and found a dramatic reduction in the expression of multiple Hypoxia-Inducible Factor (HIF)-regulated genes following MCT4 knockdown. The overall reduction in HIF transcriptional response was further validated using a hypoxia response element (HRE)-dependent green-fluorescent protein (GFP) reporter line.

Indexed as

Cell HypoxiaAnimalsApoptosisCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticGene Knockdown TechniquesGlioblastomaHumansHypoxia-Inducible Factor 1Lactic AcidMice, NudeMonocarboxylic Acid TransportersMuscle ProteinsNeoplasms, ExperimentalNeoplastic Stem CellsHypoxia-Inducible Factor 1Lactic AcidMonocarboxylic Acid TransportersMuscle ProteinsSLC16A4 protein, human

Identifiers

PMID24077291
PMCPMC4087088
OpenAlexW1971654797

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.